Glenmark launches diabetic drug


Chennai, Oct 26 : Pharma major Glenmark Pharmaceuticals Limited on Tuesday said it has launched a fixed dose combination drug for Type 2 diabetes. In a statement, Glenmark said the combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names -- Remo MV and Remozen MV. According to Glenmark, it is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination and India is the first country to get access to this drug. The company got the regulatory approval in late September 2021. Priced at Rs 16.50 per tablet, a diabetic patient has to take the tablet twice a day and cost per day works out to 53 per cent cheaper than other drugs. According to Alok Malik, Group Vice President & Business Head, India Formulations, the fixed dose combination drug will significantly improve patient compliance and provide glycemic and extra glycemic benefits to patients with uncontrolled type 2 diabetes, in India. /IANS


UK reports record rise with more than 180,000 daily Covid cases
London, Dec 30 : Britain reported a new record increase of 183,037 coronavirus cases in the latest 24-hour period, bringing the total number of corona

Omicron cases in Germany up 26% in one day: RKI
Berlin, Dec 30 : Covid-19 infections with the Omicron variant in Germany increased by 2,686, or nearly 26 per cent within one day to a total of 13,129

Vietnam reports 13,889 new Covid-19 cases
Hanoi, Dec 30 : Vietnam reported 13,889 new Covid-19 cases on Wednesday, including 13,873 locally transmitted and 16 imported, the Ministry of Health